Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
2014
EGFR Antagonists in Cancer Treatment
2008 Standout
Docetaxel Nanotechnology in Anticancer Therapy
2012
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
2012
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Lung Cancer
2008 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
2011
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
2011
Lung Cancer: Epidemiology, Etiology, and Prevention
2011 Standout
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines
2015 StandoutNobel
Prevention of VTE in Nonsurgical Patients
2012 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
2011 Standout
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
2009
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
2008
Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
2010
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
2014 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Slaying RAS with a synthetic lethal weapon
2010 StandoutNobel
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
2009
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
2012 Standout
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
2008
Combination therapy in combating cancer
2017 Standout
Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
2010
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
2011 Standout
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
2008
Works of Ming Lin being referenced
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer
2007
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer
2008